Global prevalence of pre-existing HCV variants resistant to direct-acting antiviral agents (DAAs): Mining the GenBank HCV genome data

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Chen, Zhi Wei ^a   Li, Hu ^a   Ren, Hong ^a   Hu, Peng ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PROTEINASE INHIBITOR; VIRAL PROTEIN;

ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; DRUG EFFECTS; GENE FREQUENCY; GENETIC DATABASE; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMAN; METABOLISM; PREVALENCE; VIROLOGY;

ANTIVIRAL AGENTS; DATABASES, GENETIC; DRUG RESISTANCE, VIRAL; GENE FREQUENCY; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; PREVALENCE; PROTEASE INHIBITORS; VIRAL NONSTRUCTURAL PROTEINS;

EID: 84957569270     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep20310     Document Type: Article

References (47)

1. Lavanchy, D. Chronic viral hepatitis as a public health issue in the world. Best practice & research. Clinical gastroenterology 22, 991-1008, doi: 10.1016/j.bpg.2008.11.002 (2008).
2. Manns, M. P. et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358, 958-965 (2001).
3. Hadziyannis, S. J. et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Annals of internal medicine 140, 346-355 (2004).
4. Hunt, D. & Pockros, P. What are the promising new therapies in the field of chronic hepatitis C after the first-generation direct-acting antivirals? Current gastroenterology reports 15, 303, doi: 10.1007/s11894-012-0303-3 (2013).
5. Poordad, F. et al. Boceprevir for untreated chronic HCV genotype 1 infection. The New England journal of medicine 364, 1195-1206, doi: 10.1056/NEJMoa1010494 (2011).
6. Lok, A. S. et al. Preliminary study of two antiviral agents for hepatitis C genotype 1. The New England journal of medicine 366, 216-224, doi: 10.1056/NEJMoa1104430 (2012).
7. Osinusi, A. et al. Sofosbuvir and ribavirin for hepatitis C genotype 1 in patients with unfavorable treatment characteristics: a randomized clinical trial. Jama 310, 804-811, doi: 10.1001/jama.2013.109309 (2013).
8. Zeuzem, S. Clinical implications of hepatitis C viral kinetics. Journal of hepatology 31 Suppl 1, 61-64 (1999).
9. Dahl, G., Sandstrom, A., Akerblom, E. & Danielson, U. H. Resistance profiling of hepatitis C virus protease inhibitors using full-length NS3. Antiviral therapy 12, 733-740 (2007).
10. Flint, M. et al. Selection and characterization of hepatitis C virus replicons dually resistant to the polymerase and protease inhibitors HCV-796 and boceprevir (SCH 503034). Antimicrobial agents and chemotherapy 53, 401-411, doi: 10.1128/aac.01081-08 (2009).
11. Cubero, M. et al. Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient. Virology 370, 237-245, doi: 10.1016/j.virol.2007.10.006 (2008).
12. Lu, L., Mo, H., Pilot-Matias, T. J. & Molla, A. Evolution of resistant M414T mutants among hepatitis C virus replicon cells treated with polymerase inhibitor A-782759. Antimicrobial agents and chemotherapy 51, 1889-1896, doi: 10.1128/aac.01004-06 (2007).
13. Lenz, O. et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in Phase IIb/III studies. Journal of hepatology, doi: 10.1016/j.jhep.2014.11.032 (2014).
14. Omata, M. et al. APASL consensus statements and management algorithms for hepatitis C virus infection. Hepatol Int 6, 409-435, doi: 10.1007/s12072-012-9342-y (2012).
15. EASL Recommendations on Treatment of Hepatitis C 2015. Journal of hepatology, doi: 10.1016/j.jhep.2015.03.025 (2015).
16. Wen, C. et al. Brain metabolomics in rats after administration of ketamine. Biomedical chromatography : BMC, doi: 10.1002/bmc.3518 (2015).
17. Kuntzen, T. et al. Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naive patients. Hepatology 48, 1769-1778, doi: 10.1002/hep.22549 (2008).
18. Mo Hongmei, D. B. P. Gontcharova in poster 92117 (ed AASLD) (2014).
19. Vignuzzi, M., Stone, J. K., Arnold, J. J., Cameron, C. E. & Andino, R. Quasispecies diversity determines pathogenesis through cooperative interactions in a viral population. Nature 439, 344-348, doi: 10.1038/nature04388 (2006).
20. Paolucci, S. et al. Naturally occurring resistance mutations to inhibitors of HCV NS5A region and NS5B polymerase in DAA treatment-naive patients. Virol J 10, 355, doi: 10.1186/1743-422x-10-355 (2013).
21. Yoshimi, S. et al. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. Journal of medical virology, doi: 10.1002/jmv.24255 (2015).
22. Lenz, O. et al. In vitro resistance profile of the hepatitis C virus NS3/4A protease inhibitor TMC435. Antimicrobial agents and chemotherapy 54, 1878-1887, doi: 10.1128/AAC.01452-09 (2010).
23. Bartels, D. J. et al. Hepatitis C virus variants with decreased sensitivity to direct-acting antivirals (DAAs) were rarely observed in DAA-naive patients prior to treatment. Journal of virology 87, 1544-1553, doi: 10.1128/JVI.02294-12 (2013).
24. Lam, A. M. et al. Genotype and subtype profiling of PSI-7977 as a nucleotide inhibitor of hepatitis C virus. Antimicrobial agents and chemotherapy 56, 3359-3368, doi: 10.1128/AAC.00054-12 (2012).
25. Manns, M. P. & Cornberg, M. Sofosbuvir: the final nail in the coffin for hepatitis C? The Lancet Infectious Diseases 13, 378-379, doi: 10.1016/s1473-3099(13)70074-4 (2013).
26. Asselah, T. & Marcellin, P. Interferon free therapy with direct acting antivirals for HCV. Liver international : official journal of the International Association for the Study of the Liver 33 Suppl 1, 93-104, doi: 10.1111/liv.12076 (2013).
27. Welsch, C. et al. Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. Genome Biology 9, R16, doi: 10.1186/gb-2008-9-1-r16 (2008).
28. Tong, X. et al. Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Research 70, 28-38, doi: 10.1016/j.antiviral.2005.12.003 (2006).
29. Tavis, J. E. et al. Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials. PLoS ONE 7, e34372, doi: 10.1371/journal.pone.0034372 (2012).
30. Lin, C. et al. In Vitro Resistance Studies of Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061: Structural Analysis Indicates Different Resistance Mechanisms. Journal of Biological Chemistry 279, 17508-17514, doi: 10.1074/jbc.M313020200 (2004).
31. Lin, C. In Vitro Studies of Cross-resistance Mutations against Two Hepatitis C Virus Serine Protease Inhibitors, VX-950 and BILN 2061. Journal of Biological Chemistry 280, 36784-36791, doi: 10.1074/jbc.M506462200 (2005).
32. Lenz, O. et al. In Vitro Resistance Profile of the Hepatitis C Virus NS3/4A Protease Inhibitor TMC435. Antimicrobial Agents and Chemotherapy 54, 1878-1887, doi: 10.1128/aac.01452-09 (2010).
33. Lam, A. M. et al. Genotype and Subtype Profiling of PSI-7977 as a Nucleotide Inhibitor of Hepatitis C Virus. Antimicrobial Agents and Chemotherapy 56, 3359-3368, doi: 10.1128/aac.00054-12 (2012).
34. Karino, Y. et al. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. Journal of Hepatology 58, 646-654, doi: 10.1016/j.jhep.2012.11.012 (2013).
35. Wang, C. et al. Hepatitis C Virus RNA Elimination and Development of Resistance in Replicon Cells Treated with BMS-790052. Antimicrobial Agents and Chemotherapy 56, 1350-1358, doi: 10.1128/aac.05977-11 (2012).
36. Susser, S. et al. Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 50, 1709-1718, doi: 10.1002/hep.23192 (2009).
37. Lagace, L. et al. In Vitro Resistance Profile of the Hepatitis C Virus NS3 Protease Inhibitor BI 201335. Antimicrobial Agents and Chemotherapy 56, 569-572, doi: 10.1128/aac.05166-11 (2011).
38. Kieffer, T. L. et al. Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 46, 631-639, doi: 10.1002/hep.21781 (2007).
39. Sarrazin, C. et al. Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 132, 1767-1777, doi: 10.1053/j.gastro.2007.02.037 (2007).
40. Jiang, M. et al. In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir. Antimicrob Agents Chemother 57, 6236-6245, doi: 10.1128/aac.01578-13 (2013).
41. Fridell, R. A. et al. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology 54, 1924-1935, doi: 10.1002/hep.24594 (2011).
42. Wong, K. A. et al. Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother 57, 6333-6340, doi: 10.1128/aac.02193-12 (2013).
43. Krishnan, P. et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother 59, 979-987, doi: 10.1128/aac.04226-14 (2015).
44. Pilot-Matias, T. et al. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother 59, 988-997, doi: 10.1128/aac.04227-14 (2015).
45. Kati, W. et al. In vitro activity and resistance profile of dasabuvir, a nonnucleoside hepatitis C virus polymerase inhibitor. Antimicrob Agents Chemother 59, 1505-1511, doi: 10.1128/aac.04619-14 (2015).
46. Lontok, E. et al. Hepatitis C virus drug resistance-associated substitutions: State of the art summary. Hepatology 62, 1623-1632, doi: 10.1002/hep.27934 (2015).
47. Sarrazin, C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol, doi: 10.1016/j.jhep.2015.09.011 (2015).